Schizophrenia customer story
Danish healthcare region uses remote patient monitoring tool
Copenhagen, Denmark – 23 February 2016. Monsenso, a Copenhagen-based technology company, announced today that the Zealand Healthcare Region in Denmark will use the Monsenso mHealth solution for remote patient monitoring of patients with Borderline Personality Disorder (BPD).
The objective of the pilot study is to identify and track the triggers and early warning signs of patients with borderline, as well as to gather clinical evidence with the Monsenso mHealth solution.
The pilot study will be done in collaboration with the Produktion, Forskning and Innovation Centre of the Zealand Healthcare Region in Denmark. This branch focuses on identifying pioneering solutions that have the potential to improve the productivity of hospitals and the quality of life of its patients.
Thomas Lethenborg, CEO at Monsenso ApS, said that the Zealand Healthcare Region will conduct a 20-week pilot study of 30 patients starting in March.
“The Innovation Centre of the Zealand Healthcare Region in Denmark aims to offer its patients high-quality treatment with the latest technology available. With the implementation of the Monsenso mHealth solution, clinicians will be able to access a patient’s historical aggregated data, which will help them offer a better treatment based on evidence,” said Mr Lethenborg.
Jesper Lackman, Project Manager at The Produktion, Forskning and Innovation Centre, said the pilot study would allow them to investigate the benefits of the mHealth solution to improve patient engagement.
“The Produktion, Forskning and Innovation Centre has a strong commitment towards providing patient-centred care. We are continuously looking to improve our patients’ experience and this technology will help us learn more about our patients and their behavioural patterns. Our aim is to use this technology to support the treatment we currently provide to our patients,” said Mr Lackman.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
Jesper Lakman
Innovation Facilitator
PFI – Production, Science & Innovation
+45 8171 2900
jelak@Sundhedsinnovation.com
You can download this article as PDF in English
MHealth solution receives CE Mark
Copenhagen, Denmark – 16 February 2016. Monsenso ApS, a technology leader in mobile health solutions for mental health, today announced that last Friday, its mHealth solution received a CE Mark. The double-loop treatment platform that supports the treatment of major psychiatric disorders received a Class 1 Medical Device Certification under the EU Medical Devices Directive.
The certification has been obtained due to the support received from the Market Development Fund (MMF) in May 2015, which granted 2.9 million to DKK for Monsenso and its partners to obtain the necessary certifications for the solution to be ready for an international launch.
With regards to obtaining the CE Marking Certification, Thomas Lethenborg, CEO at Monsenso, commented “Obtaining this certification is an important milestone for Monsenso since our mHealth solution is based on solid research and has already been clinically validated. Our objective with this certification is to be regarded as a medical application rather than just another app.”
A CE Marking Certification guarantees that a manufacturer’s product meets the essential requirements of all relevant European Medical Device Directives.
“Holding a CE Marking Certification and offering a high level of data security is a demand from our customers across the globe. Therefore, it is important that Monsenso can distinguish itself from all other apps with no clinical evidence or inadequate security measures” added Mr. Lethenborg.
The next step for Monsenso is to obtain the ISO 27001 Data Security Certification, the ISO 13485 Certification, and to become HIPAA and FDA compliant, which is also part of the support granted by the MMF funding.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
mHealth solution aims to reduce hospital readmissions
Copenhagen, Denmark – 9 February 2016. Monsenso ApS, a Copenhagen-based technology company, has been granted 3.065 million DKK by the Innovation Fund to develop further develop their mHealth solution that aims to reduce hospital readmissions of patients with depression and bipolar disorder.
The RADMIS research project, which has been granted a budget of 10.1 million DKK by the Innovation Fund, is being done in collaboration with the Mental Health Services of the Capital Region of Denmark (RHP) and the Danish Technical University (DTU).
Depression and bipolar disorder are the leading cause of disability worldwide, imposing a very high burden for society in terms of cost, lost productivity, and mortality. Besides, patients with affective disorders are hospitalized more frequently than any other patient group. The treatment of depression and bipolar disorder includes medication, psycho-education, and Cognitive Behavioral Therapy (CBT).
The RADMIS research project aims to establish clinical evidence that the Monsenso mHealth solution can reduce the number of hospital readmissions of patients with depression and bipolar disorder. It also seeks to decrease the symptoms and improve the quality of life of outpatients with depression or bipolar disorder receiving smartphone-based CBT.
Since smartphones are equipped with powerful sensing, computation and communication capabilities, they provide a unique platform to monitor and treat patients with depression and bipolar disorder. Moreover, smartphones also provide a rich multi-media and communication platform for Ecological Momentary Intervention (EMI) enabling patients to receive context-aware treatment in real-time, including medication reminders and CBT.
The innovation goals of the RADMIS research project are to:
- Research, design, and develop an intelligent smartphone-based monitoring and treatment platform for affective disorders
- Provide clinical evidence to reduce the number and duration of hospital re-admissions of patients with depression and bipolar disorder using smartphone-based treatment
- Provide clinical evidence that smartphone-based CBT improves the health outcomes for patients with depression and bipolar disorder
With regards to the new capabilities that will be added to the Monsenso mHealth solution, Thomas Lethenborg, CEO at Monsenso commented, “This intelligent smartphone-based monitoring and treatment platform for depression and bipolar disorders is the first of its kind; there are no similar solutions available on the market.”
“Once the clinical trial is completed, we will have the necessary evidence to prove that smartphone-based CBT helps reduce hospital readmissions of psychiatric patients. Besides, it allows health care systems to reach out to the 75% of the population in Europe who need treatment, but remain untreated,” added Mr. Lethenborg.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.comYou can download this article as PDF in English and Danish